- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.03. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 10.03. | Glucotrack, Inc.: Glucotrack to Present at LSI USA '26 Medtech Innovation Summit | 1 | GlobeNewswire (USA) | ||
| 29.01. | GlucoTrack Shares Slide 25% Despite New Patent Awards | - | RTTNews | ||
| 29.01. | Glucotrack picks up new patents for continuous blood glucose monitor | 1 | MassDevice | ||
| 29.01. | Glucotrack Stumbles Despite Winning Patent | - | Baystreet.ca | ||
| 29.01. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.01. | Glucotrack, Inc.: Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform | 190 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization... ► Artikel lesen | |
| 30.12.25 | Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor | 1 | GlobeNewswire (USA) | ||
| 29.12.25 | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Glucotrack GAAP EPS of -$4.64 | 1 | Seeking Alpha | ||
| 13.11.25 | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Glucotrack, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Glucotrack sagt außerordentliche Hauptversammlung mangels Quorum ab | 2 | Investing.com Deutsch | ||
| 06.11.25 | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.10.25 | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.10.25 | Glucotrack, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 29.09.25 | GlucoTrack files to sell 20.06M shares of common stock by selling shareholders | 1 | Seeking Alpha | ||
| 29.09.25 | Glucotrack, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 14.08.25 | GlucoTrack, Inc.: Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 361 | GlobeNewswire (Europe) | On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device... ► Artikel lesen | |
| 06.08.25 | Glucotrack, Inc.: Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology | 231 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 13,880 | -1,70 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,098 | -0,51 % | Sernova Biotherapeutics Inc: Sernova says Swetlow fired over trip, improper payouts | ||
| SYNLAB | 12,710 | 0,00 % | EQS-News: SYNLAB AG: Weitere Investitionen in Italien für modernste Diagnostik und Patientenkomfort | EQS-News: SYNLAB
/ Schlagwort(e): Strategische Unternehmensentscheidung
Weitere Investitionen in Italien für modernste Diagnostik und Patientenkomfort
23.10.2025... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,017 | +5,00 % | NuGen Medical Devices Inc.: NuGen Medical Devices Inc. Provides Update on Health Canada License | Toronto, Ontario--(Newsfile Corp. - February 5, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is initiating a temporary halt on its devices in Canada due to the lapse... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| UNIDOC HEALTH | 0,075 | +6,24 % | UniDoc stellt Installation des H3 Health Cube in Italien fertig | - Der KI-gestützte Health Cube steht
ab sofort den Patienten im Dorf Guardia Perticara in der italienischen Region Basilikata zur Verfügung.
VANCOUVER, British Columbia... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin | BOULDER, CO / ACCESS Newswire / March 18, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous... ► Artikel lesen | |
| CO-DIAGNOSTICS | 2,550 | -3,41 % | Co-Diagnostics expands South Asia distribution territory | ||
| QUIDELORTHO | 13,200 | 0,00 % | QuidelOrtho Corporation: QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio | Agreement adds new analyzer platforms and expands assay menu across key international marketsSAN DIEGO, Feb. 16, 2026 /PRNewswire/ -- QuidelOrtho has entered a long-term strategic supply... ► Artikel lesen | |
| QUEST DIAGNOSTICS | 169,35 | +0,15 % | How Is Quest Diagnostics' Stock Performance Compared to Other Healthcare Stocks? | ||
| VERU | 2,240 | -2,18 % | Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients... ► Artikel lesen | |
| LIFEWARD | 6,900 | +1,17 % | Lifeward Ltd.: Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results | Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval- Lifeward gains new... ► Artikel lesen | |
| SENSEONICS | 5,450 | -2,68 % | Senseonics reports sustained year-long CGM implant outcomes, insulin pump integration benefits | ||
| TEMPEST THERAPEUTICS | 2,280 | +5,56 % | Tempest Therapeutics: Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 | Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned... ► Artikel lesen | |
| RADNET | 53,50 | 0,00 % | RadNet auf KeyBanc-Forum: Wachstumsoptimismus und strategische Expansion |
Das Unternehmen GLUCOTRACK INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 1,040 Euro und damit -2,80 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.